NO20075113L - Proteinkinaseinhibitorer - Google Patents

Proteinkinaseinhibitorer

Info

Publication number
NO20075113L
NO20075113L NO20075113A NO20075113A NO20075113L NO 20075113 L NO20075113 L NO 20075113L NO 20075113 A NO20075113 A NO 20075113A NO 20075113 A NO20075113 A NO 20075113A NO 20075113 L NO20075113 L NO 20075113L
Authority
NO
Norway
Prior art keywords
protein kinase
kinase inhibitors
useful
present
prodrugs
Prior art date
Application number
NO20075113A
Other languages
English (en)
Norwegian (no)
Inventor
David J Bearss
Hariprasad Vankayalapati
Cory L Grand
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of NO20075113L publication Critical patent/NO20075113L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20075113A 2005-04-28 2007-10-09 Proteinkinaseinhibitorer NO20075113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67646705P 2005-04-28 2005-04-28
PCT/US2006/016423 WO2006116733A2 (fr) 2005-04-28 2006-04-28 Inhibiteurs des proteines kinases

Publications (1)

Publication Number Publication Date
NO20075113L true NO20075113L (no) 2007-11-23

Family

ID=37029567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075113A NO20075113L (no) 2005-04-28 2007-10-09 Proteinkinaseinhibitorer

Country Status (13)

Country Link
US (1) US20090029982A1 (fr)
EP (1) EP1888588A2 (fr)
JP (1) JP2008539277A (fr)
KR (1) KR20080020602A (fr)
CN (1) CN101189239A (fr)
AU (1) AU2006239236A1 (fr)
BR (1) BRPI0609956A2 (fr)
CA (1) CA2604284A1 (fr)
IL (1) IL186744A0 (fr)
MX (1) MX2007013624A (fr)
NO (1) NO20075113L (fr)
WO (1) WO2006116733A2 (fr)
ZA (1) ZA200709269B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038215A1 (fr) 2005-09-22 2007-04-05 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
EP2139869A2 (fr) * 2007-04-13 2010-01-06 SuperGen, Inc. Inhibiteurs de la kinase axl utiles pour le traitement du cancer ou de maladies hyperprolifératives
WO2009004329A1 (fr) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, et 9h-1,3,6,9-tétraaza-fluorènes en tant qu'inhibiteurs de la fonction kinase chk1
CN101801955B (zh) * 2007-07-05 2013-05-08 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US10699235B2 (en) * 2009-05-05 2020-06-30 Oracle America, Inc. System, method and computer readable medium for placing advertisements into web pages
EP2686320B1 (fr) 2011-03-15 2016-05-18 Merck Sharp & Dohme Corp. Inhibiteurs de la gyrase tricyclique
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
RU2641693C2 (ru) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
DK2807165T3 (da) * 2012-01-27 2019-07-15 Univ Montreal Pyrimido[4,5-b]indol-derivater og anvendelse deraf i ekspansionen af hæmatopoietiske stamceller
KR20210156333A (ko) 2012-05-15 2021-12-24 캔써 리서치 테크놀로지 리미티드 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
CN104804002B (zh) * 2015-04-08 2017-02-01 河南师范大学 一种9H‑嘧啶并[4,5‑b]吲哚类化合物的合成方法
AU2016273439B2 (en) 2015-06-05 2020-11-05 Héma-Québec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
CN105037374B (zh) * 2015-07-14 2017-04-12 吉林大学 N‑丁基‑9H‑嘧啶并[4,5‑b]吲哚‑2‑甲酰胺的制备方法
EP3464566A4 (fr) 2016-06-01 2020-01-08 Universite De Montreal Sélection de cellules souches hématopoïétiques humaines à l'aide de l'epcr
CA3091865A1 (fr) 2018-02-20 2019-08-29 Universite De Montreal Expansion de cellules nk et dc in vivo mediant une reponse immunitaire
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
CN114845719A (zh) * 2019-12-18 2022-08-02 蒙特利尔大学 作为抗癌化合物的cullin 3连接蛋白kbtbd4的调节剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480521T1 (de) * 1996-10-01 2010-09-15 Kyowa Hakko Kirin Co Ltd Stickstoff enthaltende heterocyclische verbindungen
WO2001021596A1 (fr) * 1999-09-21 2001-03-29 Astrazeneca Ab Derives de quinazoline et leur utilisation comme produits pharmaceutiques
CN100358890C (zh) * 2000-08-18 2008-01-02 千年药物股份有限公司 喹唑啉衍生物类激酶抑制剂
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
JP2005515173A (ja) * 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
GB0313766D0 (en) * 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds
SI1678166T1 (sl) * 2003-10-14 2009-10-31 Univ Arizona State Inhibitorji proteinske kinaze

Also Published As

Publication number Publication date
JP2008539277A (ja) 2008-11-13
ZA200709269B (en) 2009-01-28
IL186744A0 (en) 2008-02-09
AU2006239236A1 (en) 2006-11-02
EP1888588A2 (fr) 2008-02-20
CA2604284A1 (fr) 2006-11-02
WO2006116733A2 (fr) 2006-11-02
US20090029982A1 (en) 2009-01-29
BRPI0609956A2 (pt) 2010-05-18
WO2006116733A3 (fr) 2006-12-14
KR20080020602A (ko) 2008-03-05
CN101189239A (zh) 2008-05-28
MX2007013624A (es) 2008-02-12

Similar Documents

Publication Publication Date Title
NO20075113L (no) Proteinkinaseinhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
NO20082496L (no) Pyrazinderivater
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20081454L (no) Met-kinaseinhibitorer
NO20085099L (no) Puritonderivativer som HM74A agonister
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application